Withus Pharmaceutical Co

Withus Pharmaceutical Co EBIT per Employee

The EBIT per Employee of Withus Pharmaceutical Co (330350.KQ) as of Nov 10, 2026 is 29.65 M KRW. In the previous year, EBIT per Employee was 28.56 M KRW — a change of 3.80% (higher).

EBIT per Employee

29.65 MKRW

YoY

3.80%

Last updated:

EBIT per Employee of Withus Pharmaceutical Co is 2025 29.65 M KRW. EBIT per Employee of Withus Pharmaceutical Co was 2024 28.56 M KRW. It decreases by 3.80% higher compared to the previous year.

The Withus Pharmaceutical Co EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
57.25 M KRW
Jan 1, 2019
50.97 M KRW
Jan 1, 2020
7.13 M KRW
Jan 1, 2021
25.58 M KRW
Jan 1, 2022
25.54 M KRW
Jan 1, 2023
41.41 M KRW
Jan 1, 2024
28.56 M KRW
Jan 1, 2025
29.65 M KRW
The Withus Pharmaceutical Co EBIT per Employee history
YEAREBIT per EmployeeYoY
29.65 MKRW+3.80%
28.56 MKRW-31.02%
41.41 MKRW+62.15%
25.54 MKRW-0.17%
25.58 MKRW+258.63%
7.13 MKRW-86.01%
50.97 MKRW-10.97%
57.25 MKRW-3.03%
59.04 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Withus Pharmaceutical Co Stock analysis

What does Withus Pharmaceutical Co do? Withus Pharmaceutical Co Ltd is a pharmaceutical company based in Seoul, South Korea, operating within the healthcare sector. The company focuses on the manufacturing and distribution of prescription drugs, with its headquarters located in Seoul. As of the latest available information, Withus Pharmaceutical employs 191 full-time staff members. The company completed its initial public offering (IPO) on July 3, 2020, marking its entry into the public market. Its primary product categories include circulatory agents, musculoskeletal agents, digestive agents, antibiotics, and other prescription medications. Additionally, the company engages in contract manufacturing operations (CMO), providing manufacturing services for other pharmaceutical entities. Withus Pharmaceutical maintains a corporate website at https://www.withuspharm.com/mastart/mastart.php, which serves as a platform for company information and updates. The company operates in the pharmaceutical industry, contributing to the production and supply of essential medications in South Korea. Withus Pharmaceutical's business model integrates both direct product sales and contract manufacturing services, supporting its role in the broader healthcare ecosystem. The company's operations are centered around the development and delivery of prescription drugs, with a focus on key therapeutic areas such as cardiovascular health, musculoskeletal conditions, gastrointestinal treatments, and infectious disease management. The firm's activities are conducted under the regulatory framework of South Korea's pharmaceutical industry, adhering to local standards for drug manufacturing and distribution. Withus Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Withus Pharmaceutical Co stock

EBIT per Employee of Withus Pharmaceutical Co is 29.65 M KRW in 2025.

EBIT per Employee of Withus Pharmaceutical Co changed from 28.56 M KRW to 29.65 M KRW, representing a 3.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Withus Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Withus Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Withus Pharmaceutical Co

All Key Metrics — Withus Pharmaceutical Co